Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2019

View Archived Issues

Chaperone keeps prion protein on best behavior in mice and macaques

CHMFL-FLT3-335 demonstrates antitumor efficacy in vivo

Sosei initiates new clinical program with HTL-0030310 for endocrine disorders

RGFP-966, an HDAC3 inhibitor, suppresses drug-seeking behavior in rats

AJ-20064 demonstrates promising antitumor activity in lung cancer models

Positive data presented from phase II PHOENIX study of bardoxolone methyl

First patient enrolled in phase III study of troriluzole in generalized anxiety disorder

Sanofi patents new antimycobacterial compounds

Esteve Pharmaceuticals discloses new analgesics

Takeda Pharmaceutical identifies new GluN2B receptor antagonists

Torque begins first-in-human study of TRQ-1501 and plans evaluation with Keytruda

GlaxoSmithKline patents PERK inhibitors

January Therapeutics synthesizes gemcitabine prodrugs

Antitumor agent Temodal obtains additional indication approval for Ewing's sarcoma in Japan

Pluristem, NASA enter collaboration to study PLX cell therapies in space missions

New phase I study explores use of cardiac troponin activator AMG-594 in healthy subjects

FDA clears IND for phase I study of KT-1002 for IBD

Study evaluates nitisinone for 1 year in patients with oculocutaneous albinism

Mustang and National Children's Hospital partner to develop C-134 for GBM

Faron reports early observations on first patients in MATINS study of Clevegen

KEYNOTE-240 trial of Keytruda in previously treated HCC does not meet primary endpoint

Alkermes, Clovis Oncology enter collaboration to explore combination cancer therapies

DDR1 inhibitor seen to prevent renal function loss in mice

Mallinckrodt reports interim phase III results with Uvadex and Therakos platform in pediatric GvHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...